ClinicalTrials.gg
CompletedNCT00652808Updated Apr 10, 2008

Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Osteoarthritis of the Knee

A Phase 3 interventional study of valdecoxib and naproxen in Osteoarthritis and Knee, sponsored by Pfizer. Completed at 8 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-04-10.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
265
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 14 studies testing naproxen in Osteoarthritis — none open to participants now, 1 under way, none of them phase 3. Naproxen · Osteoarthritis.

Enrollment
5th of 14
265 · median 103
Started
2004
the only one that year
Phase 3
4 of 14
none open now
Registered
5th of 14
by date
Lead sponsor
6 of 14
Pfizer

Among the 14 studies testing naproxen in Osteoarthritis, this one is the 5th largest by enrollment, is the only one that started in 2004, is one of 4 in phase 3, and was the 5th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 14 studies testing naproxen in Osteoarthritis is open now. The open studies under Osteoarthritis, anywhere →

About naproxen

Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing naproxen in Osteoarthritis as a file.
02

Study summary

This study was performed to demonstrate that treatment with valdecoxib 10 mg daily (QD) was at least as effective as with naproxen 500 mg twice daily (BID), a standard non-steroidal anti-inflammatory drug (NSAID), when taken for 6 weeks in Korean subjects with symptomatic osteoarthritis (OA) of the knee. Secondary objectives were to assess the overall safety and tolerability of valdecoxib 10 mg QD taken for 6 weeks in Korean subjects with symptomatic OA of the knee.

03

Conditions studied

  • Osteoarthritis
  • Knee

Browse trials for

Keywords

  • knee, OA patients
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Korean outpatients with symptomatic radiologic evidence of OA of the knee (diagnosed according to the modified American College Rheumatology criteria)
  • Patient's Assessment of Arthritis Pain measurement of at least 40 mm on VAS
  • Patients had not received any NSAIDs or analgesics within 2 days (within 4 days for subjects taking oxaprozin, piroxicam or full dose aspirin) prior to the Baseline Visit

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of inflammatory arthritis, gout, pseudogout, Paget's disease, or any chronic pain syndrome that, in the Investigator's opinion, would interfere with the assessment of the Index Knee
  • Symptomatic anserine bursitis or acute joint trauma of the Index Knee
  • Arthroscopy performed on the Index Knee within the past 12 months
  • Complete loss of articular cartilage of the Index Knee
  • Administration of oral, or intramuscular, intravenous, or soft tissue injections of corticosterosteroids within 4 weeks prior to screening visit
  • Administration of intra-articular injection of or hyaluronic acid preparation in the Index Knee within 3 months or 6 months, respectively
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
265 participants (actual)

Study arms

  • Active comparator
    Arm 1

    Drug: valdecoxib

  • Active comparator
    Arm 2

    Drug: naproxen

Interventions

  • valdecoxib 10 mg tablet by mouth once daily for 6 weeks

  • naproxen 500 mg capsule by mouth twice daily for 6 weeks

06

What researchers measure

Primary outcomes

  1. Patient's Assessment of Arthritis Pain using a Visual Analogue Scale (OA-Pain VAS)

    Time frame: Week 6

Secondary outcomes

  1. WOMAC OA Physical Function

    Time frame: Week 2 and Week 6

  2. WOMAC OA Stiffness Index

    Time frame: Week 2 and Week 6

  3. Patient's Assessment of Arthritis Pain using a Visual Analogue Scale (OA-Pain VAS)

    Time frame: Week 2

  4. Patient's Global Assessment of Arthritis Pain using a Visual Analogue Scale (OA-Pain VAS)

    Time frame: Week 2 and Week 6

  5. adverse events

    Time frame: Continuous

  6. Physician's Global Assessment of Arthritis Pain

    Time frame: Week 2 and Week 6

  7. WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) Osteoarthritis (OA) Composite Index

    Time frame: Week 2 and Week 6

  8. WOMAC OA Pain Index

    Time frame: Week 2 and Week 6

07

Study locations

8 sites
  • Pfizer Investigational Site
    Anyang, 431-070, Korea, Republic of
  • Pfizer Investigational Site
    Gwangju, 501-757, Korea, Republic of
  • Pfizer Investigational Site
    Incheon, 405-760, Korea, Republic of
  • Pfizer Investigational Site
    Pusan, 602-739, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 110-744, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 137-701, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 138-736, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 152-703, Korea, Republic of
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2004 and a completion of Sep 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2008
First posted
Apr 4, 2008
Start
May 2004
CompletionActual
Sep 2004
Last update
Apr 10, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00652808
Lead sponsor
Pfizer
First posted
Apr 4, 2008
Start date
May 2004
Completion
Sep 2004
Last update
Apr 10, 2008

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Valdecoxib · Naproxen

Start the discussion